Targeting the BDNF-TrkB axis offers a promising therapeutic strategy, with preclinical models demonstrating that TrkB inhibitors reduce tumor growth, neural infiltration, and resistance to therapies [153,154,155]. Here, NTRK2 is linked to neoplasm.